Platelet monoamine oxidase B activity in 'de novo' and L-dopa treated parkinsonian patients and controls

3Citations
Citations of this article
6Readers
Mendeley users who have this article in their library.

Abstract

Objective: Previous studies demonstrated controversial results regarding monoamine oxidase B (MAO-B) activity in platelets in the periphery in parkinsonian patients (PD). Subjects and Methods: Therefore we determined platelet MAO-B activity in three age- and sex-matched groups of 17 untreated, so called 'de novo' patients with Parkinson's disease (PD), 17 parkinsonian patients, receiving levodopa, and 17 controls by a radio enzymatic assay. Results: No significant differences of MAO-B activity appeared. Conclusion: This result suggests that phenotypic determination of MAO-B activity in platelets may not be used as peripheral marker in PD and that levodopa treatment does not alter MAO-B activity in the periphery.

Cite

CITATION STYLE

APA

Kuhn, W., Müller, T., Gerstner, A., Winkel, R., & Goetz, M. E. (1998). Platelet monoamine oxidase B activity in “de novo” and L-dopa treated parkinsonian patients and controls. Canadian Journal of Neurological Sciences, 25(3), 249–251. https://doi.org/10.1017/S0317167100034090

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free